Holen Sie sich die Stockscreener-App
23.35
0.19%
-0.02
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Cantor Fitzgerald raises Ultragenyx stock price target on therapy outlook By Investing.com - Investing.com Canada
Ultragenyx Earnings Call Balances Growth and Cash Burn - TipRanks
Ultragenyx Pharmaceutical stock (US74930A1043): Shareholders back incentive plan - AD HOC NEWS
Ultragenyx director Suliman Shehnaaz sells $144,188 in stock By Investing.com - Investing.com Australia
Ultragenyx director Suliman Shehnaaz sells $144,188 in stock - Investing.com
Ultragenyx (RARE) director receives RSU and stock option grants in new Form 4 - Stock Titan
Ultragenyx (RARE) director sells shares and receives RSU and option awards - Stock Titan
Ultragenyx (RARE) director granted RSUs and stock options as compensation - Stock Titan
Ultragenyx (RARE) director receives RSU and stock option grants - Stock Titan
Ultragenyx (RARE) director Narachi receives RSU and option awards - Stock Titan
[Form 4] Ultragenyx Pharmaceutical Inc. Insider Trading Activity - Stock Titan
Ultragenyx (RARE) director Deborah Dunsire granted RSUs and new stock options - Stock Titan
[144] Ultragenyx Pharmaceutical Inc. SEC Filing - Stock Titan
Ultragenyx Shareholders Approve Incentive Plan, Elect Directors - TipRanks
Ultragenyx shareholders approve director elections and incentive plan at annual meeting - Investing.com
Ultragenyx (RARE) investors approve incentive plan, board slate and 2026 auditor - Stock Titan
Rare Q1 loss wider than expected, sales down Y/Y on seasonal effect - MSN
Chancery Court Tosses Stockholder Complaint Against Ultragenyx Pharma - Courthouse News
Ultragenyx Pharmaceutical Inc.Common Stock (NQ: RARE - The Chronicle-Journal
Ultragenyx Pharmaceutical Sees Unusually Large Options Volume (NASDAQ:RARE) - MarketBeat
UBS Group AG Raises Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Insiders Sold US$3.3m Of Shares Suggesting Hesitancy - 富途牛牛
HC Wainwright Has Bearish Forecast for RARE Q2 Earnings - MarketBeat
Investigation Alert: Long-Term Investors in Ultragenyx - openPR.com
RARE: Upcoming gene therapy launches and Angelman data drive growth toward 2027 profitability - TradingView
State Street (RARE) reports 5.1% ownership, 5,021,441 shares - Stock Titan
HC Wainwright Brokers Decrease Earnings Estimates for RARE - MarketBeat
State of New Jersey Common Pension Fund D Sells 42,451 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
GTX-102 data show continued developmental gains in Angelman - Angelman Syndrome News
Earnings call transcript: Ultragenyx Q1 2026 sees revenue miss, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: Ultragenyx Q1 2026 sees revenue miss, stock rises - Investing.com India
CCORF Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $79 - Moomoo
H.C. Wainwright Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Number of shareholders of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Number of shareholders of Ultragenyx Pharmaceutical, Inc. – FWB:UP0 - TradingView
Ultragenyx Pharmaceutical (RARE) Valuation Check After Recent Share Price Momentum And Long Term Pressure - Sahm
Ultragenyx Pharmaceutical (NASDAQ:RARE) Cut to "Strong Sell" at Wall Street Zen - MarketBeat
Is Ultragenyx (RARE) Reaffirming 2026–2027 Guidance Enough To Offset Its Widening Losses? - Yahoo Finance
RARE SEC FilingsUltragenyx Pharm 10-K, 10-Q, 8-K Forms - Stock Titan
Vanguard Group Inc. Buys 131,087 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Fluctuations - Markets Mojo
Ultragenyx Pharmaceutical (RARE) Is Up 5.8% After Reaffirming 2026 Outlook Despite Wider Losses – What's Changed - Sahm
RARE Maintained by Wedbush -- Price Target Lowered to $26 - GuruFocus
RARE Maintained by Guggenheim -- Price Target Lowered to $43 - GuruFocus
Guggenheim Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $43.00 - MarketBeat
Guggenheim Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Cuts Target Price to $43 - Moomoo
Ultragenyx to Present at Bank of America Healthcare Conference on May 13, 2026 - geneonline.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2026 Earnings Call Transcript - Insider Monkey
Rare disease families find roadmap to drug development at bootcamps - CNBC
Ultragenyx Pharmaceutical (RARE) Heavy Q1 EPS Loss Tests Bulls Profitability Timeline Narrative - Sahm
RBC Capital Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Ultragenyx Earnings Call: Growth, Gene Therapy and Risk - TipRanks
Ultragenyx Pharmaceutical Inc. 2024 SEC Filing: Financial Information, Forward-Looking Statements, and Market Risks - Minichart
Ultragenyx investors can watch CFO at Bank of America panel May 12 - Stock Titan
Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference - The Manila Times
0.06%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):